Akari Therapeutics
AKTX
14 hedge funds and large institutions have $1.99M invested in Akari Therapeutics in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 0 closing their positions.
17% more funds holding
Funds holding: 12 → 14 (+2)
0% less ownership
Funds ownership: 0% → 0% (-0%)
12% less capital invested
Capital invested by funds: $2.27M → $1.99M (-$281K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$25.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$145K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$24.5K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$10.9K |
| 4 |
HF
HRT Financial
New York
|
-$4.08K |
| 5 |
Morgan Stanley
New York
|
-$1.36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OFW
1
Omnia Family Wealth
Aventura,
Florida
| $761K | – | – | – |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $737K | – | – | – |
|
|
HP
3
Hikari Power
Tokyo,
Japan
| $146K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $107K | -$145K | -107 | -57% |
|
|
5
Citadel Advisors
Miami,
Florida
| $62K | -$24.5K | -18 | -28% |
|
6
Geode Capital Management
Boston,
Massachusetts
| $49K | – | – | – |
|
|
7
HighTower Advisors
Chicago,
Illinois
| $33K | -$10.9K | -8 | -24% |
|
|
HF
8
HRT Financial
New York
| $31K | -$4.08K | -3 | -11% |
|
|
9
Millennium Management
New York
| $25K | +$25.8K | +19 | New |
|
10
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $20K | – | – | – |
|
|
11
Morgan Stanley
New York
| $9K | -$1.36K | -1 | -13% |
|
12
Bank of America
Charlotte,
North Carolina
| $5K | – | – | – |
|
|
TC
13
Truvestments Capital
Sarasota,
Florida
| $3K | – | – | – |
|
|
14
UBS Group
Zurich,
Switzerland
| $2K | +$1.36K | +1 | New |
|
AKTX Hedge Fund Activity: Q3 2021 in Review
14 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q3 2021, worth a combined $1.99M — down 12% from $2.27M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new AKTX positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $25.8K. The largest seller was Renaissance Technologies, cutting an estimated $145K.
- 14 institutional investors held Akari Therapeutics (AKTX) as of Q3 2021, up from 12 in Q2 2021.
- Funds reported $1.99M of Akari Therapeutics stock for Q3 2021, down 12% quarter-over-quarter.
- 2 funds opened new Akari Therapeutics positions in Q3 2021 and 0 closed out, a net change of +2 holders.
- The largest Akari Therapeutics buyer in Q3 2021 was Millennium Management, an estimated $25.8K added.
- The largest Akari Therapeutics seller in Q3 2021 was Renaissance Technologies, an estimated $145K sold.
Based on aggregated 13F filings for Q3 2021.